LAG3 and gastric cancer: Furthermore, we observed an intriguing partial response in a patient with metastatic GC who participated in a phase 1b clinical trial evaluating MGD013 (bi-specific antibody targeting PD-1 and LAG-3) in combination with niraparib (ClinicalTrials.gov Identifier: NCT04178460) (Fig. 6a).